Drug Trial Radar · NCT06137144
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
161
Planned (sponsor's estimate)
Start
Jan 23, 2024
Primary completion
May 3, 2029
Study completion May 3, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Nov 18, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.
Conditions
- Lymphoma
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Peripheral T-cell Lymphoma (PTCL)
- PTCL-NOS
- ALCL
- AITL
Interventions
AZD3470Drug
AZD3470 is a novel, potent and selective, second-generation, Methylthioadenosine (MTA)-selective, small molecule inhibitor of PRMT5.
PembrolizumabDrug
Pembrolizumab (CAS nr: 1374853-91-4 )
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: From Screening continuously until 28 days after the last dose of study medication.
- Incidence of DLTs (Dose Escalation Cohorts only)Time frame: From first dose of AZD3470 to end of Cycle 1 (each cycle is 21 days).
Locations
38 sites in 11 countries. Site status is shown where the registry gives one.
Research Site
Duarte, California · Recruiting
Research Site
Miami, Florida · Recruiting
Research Site
Atlanta, Georgia · Withdrawn
Research Site
Boston, Massachusetts · Recruiting
Research Site
New York, New York · Recruiting
Research Site
Philadelphia, Pennsylvania · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Adelaide, Australia · Withdrawn
Research Site
Birtinya, Australia · Withdrawn
Research Site
Fitzroy, Australia · Recruiting
Research Site
Nedlands, Australia · Recruiting
Research Site
South Brisbane, Australia · Withdrawn
Research Site
Waratah, Australia · Withdrawn
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
Beijing, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Shanghai, China · Recruiting
Research Site
Créteil, France · Terminated
Research Site
Dijon, France · Recruiting
Research Site
Lille, France · Recruiting
Research Site
Pierre-Bénite, France · Recruiting
Research Site
Villejuif, France · Recruiting
Research Site
Berlin, Germany · Not yet recruiting
Research Site
Cologne, Germany · Recruiting
Research Site
Erlangen, Germany · Not yet recruiting
Research Site
Würzburg, Germany · Recruiting
Research Site
Alessandria, Italy · Recruiting
Research Site
Bologna, Italy · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Bunkyō City, Japan · Recruiting
Research Site
Kōtoku, Japan · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
Seoul, South Korea · Recruiting
Research Site
L'Hospitalet de Llobregat, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Research Site
Manchester, United Kingdom · Recruiting
Research Site
Oxford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.